Introducing RSP’s patented GlucoBeam  TGM technology

RSP’s patented technology advances the field by light years

GlucoBeam technology

The world’s best touch glucose monitoring technology

RSP has developed and clinically verified a non-invasive technology by applying new innovation to a well-understood principle

Highlights:

  • Advanced technology in optics and AI
  • Broad and comprehensive patent protection
  • Multi-center clinical testing of technology performance
  • Comprehensive plans for technology miniaturization to watch size
  • RSP plans to pursue FDA clearance based on completion of over 25 clinical and usage studies
  • Defining and planning a go-to-market strategy
  • Ongoing investor-partner discussions with industry majors
Play Video

How GlucoBeam works

This all-in-one technology system combines Raman spectroscopy and RSP-proprietary Critical Depth technologies to create touch glucose monitoring

unnamed

User touches the screen with base of thumb
and a beam of light shines on the skin

unnamed middle

Light scattered from the skin is collected and processed using artificial intelligence (AI)

unnamed right

Glucose measurement is displayed within a minute

Robust intellectual property

Critical Depth

Apparatus patent covering Critical Depth measurements enabling sustainable calibration and thus practical use.

Pre-validation

Method patent claiming the use of primary spectral data for gauging quality of measurement.   

Hybrid Detection

Apparatus patent claiming reduced size spectrometer technology. Enabling overall reduced footprint and future lowering of COGS.

Our highly skilled team have advanced the technological application of Raman spectroscopy to be used to non-invasively measure relevant molecules in human tissue.

These advancements are the result of a decade long R&D and pre-clinical study program during which we refined Raman technology, focusing on improving the optical system, electronics, and data analysis algorithms.

Furthermore, we have carefully developed the know-how of in-vivo measurements required to:

  • Selectively and efficiently collect Raman signal from the interstitial fluid and cells
  • Analyze spectral data to derive the concentration of a given molecule
  • Build a calibration model and use it for deriving concentration values from measurements

In the process, we have discovered and patented fundamental aspects of Raman detection of glucose and other substances in human tissue. This removes the dependence of signal calibration on the probe position, allowing for unprecedented performance.

R&D for GlucoBeam technology

RSP’s R&D program is continually optimizing the mathematical algorithms for converting spectral data to sugar concentrations in the skin. Clarke Error grid study suggests positive testing outcome:

  • “Real world” test parameters show excellent performance under normal home use without supervision.  These conditions were used to determine true baseline performance (study not clinically controlled to optimize or boost outcomes)
  • Avenues for improvements.
  • RSP’s program is continually optimizing the mathematical algorithms for converting spectral data to sugar concentrations in the skin1
1 Source: RSP early, indicative internal data from preliminary testing

Overview of technology

Main Elements of GlucoBeam

Battery-powered and rechargable

Microcontroller for system control, data analysis, and display control

Wifi and Bluetooth Connection

Capacitive touch display

Safety measures designed to prevent laser working when no hand is on

830nm wavelength grating stabilized laser

Lens system for beam shaping and signal collection

High sensitive transmission grating based miniaturized Raman spectrometer with a spectral range of 850-960nm  

Awarded €2.4m grant by Horizon 2020 to continue research and development